A For­bion-fund­ed start­up bought the rights to Am­gen's CETP in­hibitor, and is giv­ing the cho­les­terol drug an­oth­er go

For­bion-fund­ed start­up NewAms­ter­dam Phar­ma has ac­quired the rights to obice­trapib: the CETP in­hibitor that CEO Michael David­son al­ways thought would be the “crown­ing” of his ca­reer.

The an­nounce­ment comes five years af­ter For­bion sold Dez­i­ma Phar­ma and obice­trapib, its sole prod­uct, to Am­gen for an up-front pay­ment of $300 mil­lion. Am­gen halt­ed de­vel­op­ment in 2017, short­ly af­ter Eli Lil­ly, Pfiz­er, Roche and Mer­ck walked away from their own CETP drugs. For­mer Pfiz­er R&D chief John LaMat­ti­na even sug­gest­ed that Am­gen might be bet­ter off cut­ting its loss­es just weeks af­ter ac­quir­ing the drug.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN